AR070236A1 - Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto - Google Patents
Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuestoInfo
- Publication number
- AR070236A1 AR070236A1 ARP090100205A ARP090100205A AR070236A1 AR 070236 A1 AR070236 A1 AR 070236A1 AR P090100205 A ARP090100205 A AR P090100205A AR P090100205 A ARP090100205 A AR P090100205A AR 070236 A1 AR070236 A1 AR 070236A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidin
- oxo
- methyl
- acid
- enantiomerically pure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente se refiere a ácido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4H-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro o a sales farmacéuticamente aceptables del mismo, estando éste en estado solido, a su uso en terapia médica, a una composicion farmacéutica que lo comprende, a su uso en la preparacion de un medicamento para utilizar en un método para prevenir o tratar enfermedades, y a su uso en un método para prevenir o tratar enfermedades. La presente se refiere a un inhibidor selectivo de la fosfoinositide (Pl) 3-quinasa beta y al uso del inhibidor selectivo por ejemplo en la terapia antitrombotica. Estos compuestos son utiles para tratar trombos plaquetarios, ataques isquémicos, angina inestable e isquemia aguda de extremidades y organos internos. Reivindicacion 7: El enantiomero puro de acuerdo con cualquiera de las reivindicaciones 1 a 6, que se caracteriza por tener picos de XRPD en los siguientes valores d aproximados: 6,8; 5,9 y 3,91 L. Reivindicacion 8: El enantiomero puro de acuerdo con cualquiera de las reivindicaciones 1 a 6, que se caracteriza por tener picos de XRPD en los siguientes valores d aproximados: 6,8; 6,1; 5,9; 4,98; 4,41; 4,26 y 3,91 L. Reivindicacion 9: Ácido (-) 2-[(1R)-1-(7-metil-2-(morfolin-4-il)-4-oxo-4H-pirido[1,2- a]pirimidin-9-il]etilamino]benzoico de acuerdo con la reivindicacion 7 o con la reivindicacion 8 que se caracteriza por tener un difractograma de XRPD esencialmente segun se muestra en la FIGURA 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2349808P | 2008-01-25 | 2008-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070236A1 true AR070236A1 (es) | 2010-03-25 |
Family
ID=40899463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100205A AR070236A1 (es) | 2008-01-25 | 2009-01-23 | Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090191177A1 (es) |
EP (1) | EP2245030A4 (es) |
JP (1) | JP2011510071A (es) |
KR (1) | KR20100118977A (es) |
CN (1) | CN101925601A (es) |
AR (1) | AR070236A1 (es) |
AU (1) | AU2009206804A1 (es) |
BR (1) | BRPI0906805A2 (es) |
CA (1) | CA2712022A1 (es) |
CL (1) | CL2009000148A1 (es) |
MX (1) | MX2010008097A (es) |
PE (1) | PE20091402A1 (es) |
RU (1) | RU2010133715A (es) |
TW (1) | TW200936138A (es) |
UY (1) | UY31609A1 (es) |
WO (1) | WO2009093972A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
US8815853B2 (en) | 2010-12-23 | 2014-08-26 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
CN104592222B (zh) * | 2014-12-26 | 2016-08-24 | 苏州明锐医药科技有限公司 | 抗血小板药物azd6482的制备方法 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
JP2023526058A (ja) * | 2020-05-14 | 2023-06-20 | ザ ハート リサーチ インスティテュート リミテッド | 抗血小板剤による血栓症及び関連疾患の治療 |
IL307950A (en) | 2021-05-03 | 2023-12-01 | Petra Pharma Corp | Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases |
AU2022282380A1 (en) | 2021-05-27 | 2023-12-07 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer |
TW202334137A (zh) * | 2021-11-03 | 2023-09-01 | 美商薩諾管理公司 | Pi3k抑制劑及治療癌症之方法 |
WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
WO2023207881A1 (en) * | 2022-04-24 | 2023-11-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
WO2024051778A1 (en) * | 2022-09-09 | 2024-03-14 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
WO2024081889A1 (en) * | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7998291A (en) * | 1990-06-20 | 1992-01-07 | Upjohn Company, The | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
ATE363471T1 (de) * | 2000-01-24 | 2007-06-15 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
CA2495661C (en) * | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
-
2009
- 2009-01-22 WO PCT/SE2009/050065 patent/WO2009093972A1/en active Application Filing
- 2009-01-22 RU RU2010133715/04A patent/RU2010133715A/ru not_active Application Discontinuation
- 2009-01-22 CN CN2009801035429A patent/CN101925601A/zh active Pending
- 2009-01-22 MX MX2010008097A patent/MX2010008097A/es not_active Application Discontinuation
- 2009-01-22 AU AU2009206804A patent/AU2009206804A1/en not_active Abandoned
- 2009-01-22 JP JP2010544271A patent/JP2011510071A/ja active Pending
- 2009-01-22 EP EP09703707A patent/EP2245030A4/en not_active Withdrawn
- 2009-01-22 KR KR1020107017149A patent/KR20100118977A/ko not_active Application Discontinuation
- 2009-01-22 BR BRPI0906805-8A patent/BRPI0906805A2/pt not_active IP Right Cessation
- 2009-01-22 CA CA2712022A patent/CA2712022A1/en not_active Abandoned
- 2009-01-23 TW TW098103073A patent/TW200936138A/zh unknown
- 2009-01-23 UY UY031609A patent/UY31609A1/es unknown
- 2009-01-23 PE PE2009000099A patent/PE20091402A1/es not_active Application Discontinuation
- 2009-01-23 CL CL2009000148A patent/CL2009000148A1/es unknown
- 2009-01-23 AR ARP090100205A patent/AR070236A1/es unknown
- 2009-01-25 US US12/359,323 patent/US20090191177A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009093972A1 (en) | 2009-07-30 |
JP2011510071A (ja) | 2011-03-31 |
EP2245030A1 (en) | 2010-11-03 |
BRPI0906805A2 (pt) | 2015-07-14 |
MX2010008097A (es) | 2010-08-04 |
PE20091402A1 (es) | 2009-10-21 |
KR20100118977A (ko) | 2010-11-08 |
AU2009206804A1 (en) | 2009-07-30 |
US20090191177A1 (en) | 2009-07-30 |
CL2009000148A1 (es) | 2010-10-15 |
EP2245030A4 (en) | 2012-03-21 |
CA2712022A1 (en) | 2009-01-30 |
TW200936138A (en) | 2009-09-01 |
RU2010133715A (ru) | 2012-02-27 |
CN101925601A (zh) | 2010-12-22 |
UY31609A1 (es) | 2009-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070236A1 (es) | Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto | |
AR058904A1 (es) | Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo | |
CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
RS52245B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use | |
BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
CL2020000283A1 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
ECSP088414A (es) | Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria | |
WO2006110917A3 (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
MY145694A (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
WO2008046084A3 (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
ECSP088963A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden | |
CO6251286A2 (es) | Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2 | |
AR068438A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
PE20090166A1 (es) | Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas | |
CR11823A (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |